Table 1.
Feature | Multiple sclerosis | Progressive multifocal leukoencephalopathy |
---|---|---|
Clinical features | ||
Onset | Acute | Subacute |
Evolution |
|
|
Clinical presentation |
|
|
MRI features | ||
Aspect and location of new lesions | Focal, generally periventricular in location. Lesions occur in all areas of the brain particularly the corpus callosum and spinal cord | Diffuse. Generally large >3 cm lesions in a unifocal, multifocal or widespread distribution. Subcortical location rather than periventricular. Affecting U fibres and extending into the gyrus. Cortical GM involvement in 50% of cases. Posterior fossa less frequent site. Spinal cord presentation rare |
Borders | Sharp edges; mostly round or flame shaped (especially periventricular lesions), confluent with other lesions; U-fibres may be involved | Irregular in shape. Ill-defined border toward the white matter, sharp border toward the cortical grey matter |
Mode of extension | Initially focal, lesions enlarge within days or weeks and later decrease in size within months | Lesion volume increases continuously, and sometimes rapidly to contiguous (multifocal) and non-contiguous regions (widespread) confined to white matter tracts, sparing the cortex |
Mass effect | Large acute lesions may have mass effect | No mass effect even in large lesions apart from when inflammatory response is present |
On T2-weighted sequence | Homogeneous hyperintensity | Diffuse hyperintensity, little irregular signal intensity within the lesions, can have a punctate microcystic appearance. Small punctate T2 lesions may be seen in proximity to the lesion |
On T1-weighted sequence | Acute lesions: hypointense (due to oedema) or isointense. Increasing signal intensity over time in 80%; decreasing signal intensity (axonal loss) in about 20% | Slightly hypointense at onset, with signal intensity decreasing over time in the affected area; no reversion to isointense signal intensity |
On FLAIR sequence | Hyperintense, sharply delineated | FLAIR is the preferred sequence for PML diagnosis, because of the subcortical location |
Contrast enhancement | Acute lesions: homogeneous nodular or ring enhancement, with sharp edges eventual resolution over 1–2 months. Chronic lesions: no enhancement | Less than half of the cases to date have shown some enhancement at the time of presentation often with a patchy or punctate appearance. Rim enhancement at leading edge can be seen in larger lesions |
Diffusion-weighted imaging | Acute lesions hyperintense. Chronic lesions isointense. Conforms to shape of lesions on FLAIR and T2W | Acute PML lesions are hyperintense but not specific for PML. Helpful to detect new PML lesions within confluent areas of chronic WM disease. ADC maps not helpful |
Atrophy | Focal atrophy possible, due to focal white-matter degeneration; no progression | No focal atrophy initially, but can be seen in late stages of PML progression |
It should be noted that none of the MRI features are pathognomonic of MS or PML. Adapted from Physician information and management guidelines for multiple sclerosis patients on Tysabri therapy, Biogen, V.14, 22 May 2015 (permission obtained).
ADC, Apparent diffusion coefficient; FLAIR, fluid-attenuated inversion recovery; GM, grey matter; MS, multiple sclerosis; PML, progressive multifocal leukoencephalopathy; T2W, T2 weighted; WM, white matter.